drugset / Trial / NCT04258072
Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.
NaSingle-groupOpen-labelTreatment
Summary
To determine recommended phase 2 dose and to evaluate the safety of vactosertib in combination with nal-IRI/FL in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have failed first-line gemcitabine and nab-paclitaxel
Timeline
- Start
- 2021-04-19
- Primary completion
- 2022-12
- Completion
- 2023-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vactosertib | Small molecule | 100 mg | — |
| Subject | Vactosertib | Small molecule | 300 mg | — |